Cargando…
Sildenafil citrate and uteroplacental perfusion in fetal growth restriction
BACKGROUND: To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion. MATERIALS AND METHODS: Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 w...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685778/ https://www.ncbi.nlm.nih.gov/pubmed/23798922 |
_version_ | 1782273735733018624 |
---|---|
author | Dastjerdi, Marzieh Vahid Hosseini, Sayedehafagh Bayani, Leila |
author_facet | Dastjerdi, Marzieh Vahid Hosseini, Sayedehafagh Bayani, Leila |
author_sort | Dastjerdi, Marzieh Vahid |
collection | PubMed |
description | BACKGROUND: To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion. MATERIALS AND METHODS: Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestation were evaluated for the effect of a single dose of Sildenafil citrate on uteroplacental circulation as determined by Doppler ultrasound study of the umbilical and middle cerebral arteries. Statistical analysis included χ(2)-test to compare proportions, and independent-samples t-test and paired student's t-test to compare continuous variables. RESULTS: Sildenafil group fetuses demonstrated a significant decrease in systolic/diastolic ratios (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000), and pulsatility index (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019) for the umbilical artery and a significant increase in middle cerebral artery pulsatility index (MCA PI) (0.51 [SD 0.60] [95% Cl 0.16-0.85], P=0.008). CONCLUSION: Doppler velocimetry index values reflect decreased placental bed vascular resistance after Sildenafil. Sildenafil citrate can improve fetoplacental perfusion in pregnancies complicated by intrauterine growth restriction. It could be a potential therapeutic strategy to improve uteroplacental blood flow in pregnancies with fetal growth restriction (FGR). |
format | Online Article Text |
id | pubmed-3685778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36857782013-06-24 Sildenafil citrate and uteroplacental perfusion in fetal growth restriction Dastjerdi, Marzieh Vahid Hosseini, Sayedehafagh Bayani, Leila J Res Med Sci Original Article BACKGROUND: To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion. MATERIALS AND METHODS: Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestation were evaluated for the effect of a single dose of Sildenafil citrate on uteroplacental circulation as determined by Doppler ultrasound study of the umbilical and middle cerebral arteries. Statistical analysis included χ(2)-test to compare proportions, and independent-samples t-test and paired student's t-test to compare continuous variables. RESULTS: Sildenafil group fetuses demonstrated a significant decrease in systolic/diastolic ratios (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000), and pulsatility index (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019) for the umbilical artery and a significant increase in middle cerebral artery pulsatility index (MCA PI) (0.51 [SD 0.60] [95% Cl 0.16-0.85], P=0.008). CONCLUSION: Doppler velocimetry index values reflect decreased placental bed vascular resistance after Sildenafil. Sildenafil citrate can improve fetoplacental perfusion in pregnancies complicated by intrauterine growth restriction. It could be a potential therapeutic strategy to improve uteroplacental blood flow in pregnancies with fetal growth restriction (FGR). Medknow Publications & Media Pvt Ltd 2012-07 /pmc/articles/PMC3685778/ /pubmed/23798922 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Dastjerdi, Marzieh Vahid Hosseini, Sayedehafagh Bayani, Leila Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title | Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title_full | Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title_fullStr | Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title_full_unstemmed | Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title_short | Sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
title_sort | sildenafil citrate and uteroplacental perfusion in fetal growth restriction |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685778/ https://www.ncbi.nlm.nih.gov/pubmed/23798922 |
work_keys_str_mv | AT dastjerdimarziehvahid sildenafilcitrateanduteroplacentalperfusioninfetalgrowthrestriction AT hosseinisayedehafagh sildenafilcitrateanduteroplacentalperfusioninfetalgrowthrestriction AT bayanileila sildenafilcitrateanduteroplacentalperfusioninfetalgrowthrestriction |